Harrow Announces Market Access Wins for VEVYE®

HROWL 11.12.2024

Full Press ReleaseSEC FilingsOur HROWL Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.21.2024 - Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Recent Filings

  • 01.21.2025 - 8-K Current report
  • 01.08.2025 - 3 Initial statement of beneficial ownership of securities
  • 01.08.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

NASHVILLE, Tenn.--(BUSINESS WIRE)--Nov. 12, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. StartingJanuary 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna,Kaiser Permanente, and CVS Caremark. In the aggregate, these sponsors represent over 25 million Medicare Part D beneficiaries.

In addition to Medicare Part D, VEVYE has achieved broad coverage across other major insurance programs, including 100% ofU.S.Medicaid programs and 60% of commercial insurance coverage. This breadth of coverage underscores Harrow’s commitment to ensuring that patients, regardless of their insurance type, have access to effective treatment for chronic dry eye disease (DED), a condition that affects millions of Americans and is especially impactful to older adults.

“Medicare access is essential for VEVYE’s continued successful progression as a preferred dry eye disease prescription choice, and we’re thrilled that we’ve secured these initial Medicare Part D formulary coverages – including with some of the largest 2025 Medicare Part D payers,” saidMark L. Baum, Chairman and Chief Executive Officer of Harrow. “For too long, Medicare beneficiaries have lacked an accessible, effective, and highly tolerable dry eye treatment. With 67 million Medicare beneficiaries in theU.S., including the 54 million with Medicare Part D prescription coverage, there is a substantial need for the unique clinical benefits that VEVYE offers. The prevalence of DED rises with age, and seniors face an increased risk for this chronic condition, affecting their comfort, vision, and overall quality of life. With this expanded access, we can better serve Medicare beneficiaries by improving their eye health, independence, and quality of life.”

About VEVYE

VEVYE®(cyclosporine ophthalmic solution) 0.1%, a patented, non‐preserved, twice-daily (BID) dosed prescription drug based on a “water‐free” semifluorinated alkane eyedrop technology, is uniquely dispensed in a 10 microliter drop and is the first and only cyclosporine‐based product indicated for treating both the signs and symptoms of dry eye disease (DED).

About Dry Eye Disease

Dry eye disease (DED) is a common condition that occurs when the eyes do not produce enough tears or when the tears evaporate too quickly, and it is often associated with chronic inflammation. Untreated DED can lead to discomfort such as stinging, burning or blurry vision, and chronic DED can interfere with daily activities like reading and using a computer. More serious consequences include increased risk of eye infections and damage to the surface of the eye, which can potentially result in serious vision problems and even loss of sight. Causes of dry eye are varied and can include aging, certain medications, medical conditions, or environmental factors such as increased screen time and exposure to pollutants, all of which are contributing to a forecast of continued significant increase in DED. According to a 2020 report fromMarket Scope, DED affects more than 38 million Americans. In addition, 92% of this patient population remains un- or under-treated due to limited efficacy and poor tolerability of existing prescription and non-prescription choices.1

1Source:Ophthalmology Innovation Source (OIS) Dry Eye Conference(March 2021)

About Harrow

Harrow, Inc.(Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of theU.S.Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with theSecurities and Exchange Commission(SEC), including its Annual Report on Form 10-K for the year endedDecember 31, 2023, subsequent Quarterly Reports on Form 10-Q and other filings with theSEC. Such documents may be read free of charge on theSEC'sweb site atsec.gov. Undue reliance should not be placed on forward‐looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241112120889/en/

InvestorsJamie WebbDirector of Communications and Investor Relationsjwebb@harrowinc.com615-733-4737

MediaDeb HollidayHolliday Communications, Inc.deb@hollidaycommunications.net412-877-4519

Source:Harrow, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com